LMR Partners’s Moderna MRNA Stock Holding History

LMR Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.5K	Sell	699 -103,068	-99%	-$4.81M	﹤0.01%	1327
2025 Q4	$3.06M	Buy	103,767 +70,958	+216%	+$1.93M	0.01%	710
2025 Q3	$847K	Sell	32,809 -19,944	-38%	-$556K	﹤0.01%	989
2025 Q2	$1.46M	Buy	52,753 +41,353	+363%	+$1.09M	0.01%	711
2025 Q1	$323K	Buy	+11,400	New	+$405K	﹤0.01%	994
2024 Q4	–	Sell	-350,133	Closed	-$16.7M	–	1463
2024 Q3	$23.4M	Buy	350,133 +296,232	+550%	+$27.2M	0.19%	97
2024 Q2	$6.4M	Buy	+53,901	New	+$6.82M	0.05%	276
2022 Q3	–	Sell	-45,844	Closed	-$6.55M	–	1277
2022 Q2	$6.55M	Sell	45,844 -31,459	-41%	-$4.5M	0.11%	229
2022 Q1	$13.3M	Buy	+77,303	New	+$13M	0.15%	142
2021 Q2	–	Sell	-35,100	Closed	-$4.6M	–	1253
2021 Q1	$4.6M	Sell	35,100 -75,996	-68%	-$11M	0.11%	169
2020 Q4	$11.6M	Sell	111,096 -188,163	-63%	-$19M	0.18%	61
2020 Q3	$21.2M	Buy	+299,259	New	+$20.9M	0.44%	31

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LMR Partners's MRNA Position: Q1 2026 in Review

LMR Partners reduced its Moderna (MRNA) stake by 99% in Q1 2026, selling an estimated $4.81M and leaving 699 shares worth $35.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1327.

LMR Partners first reported a position in MRNA in Q3 2020 and has held it in 12 quarters since. The position peaked at $23.4M in Q3 2024. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

LMR Partners held 699 shares of Moderna worth $35.5K as of Q1 2026.
LMR Partners sold 103,068 Moderna shares in Q1 2026, an estimated $4.81M.
Moderna made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1327 holding.
LMR Partners first reported a position in Moderna in Q3 2020 and has held it in 12 quarters since.
LMR Partners's Moderna position peaked at $23.4M in Q3 2024.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.